Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

Cartesian Therapeutics (NASDAQ: RNAC), a late clinical-stage biotech developing cell therapies for autoimmune diseases, will join a fireside chat at the H.C.

Rhea-AI Summary

Cartesian Therapeutics (NASDAQ: RNAC), a late clinical-stage biotech developing cell therapies for autoimmune diseases, will join a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on May 19, 2026, at 3:00 p.m. ET. A live and archived webcast will be available on its website.

Argus May 12 session

+1.99% close to close Open Argus

Details

News Market Reaction – RNAC

In the May 12 session, RNAC gained 1.99%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Cartesian’s continued participation in investor conferences, adding ano...

Analysis

This announcement highlights Cartesian’s continued participation in investor conferences, adding another scheduled fireside chat on May 19, 2026 at 3:00 p.m. ET. Historically, the company has paired such visibility with regular financial updates, cash runway disclosures, and progress across its Descartes-08 trials. Investors may focus on how management uses this venue to frame clinical milestones, cash utilization, and strategic priorities relative to recent quarterly and annual filings.

Key Figures

Conference edition: 4th Annual BioConnect Investor Conference Conference date/time: May 19, 2026 at 3:00 p.m. ET

Conference edition

4th Annual BioConnect Investor Conference

Investor conference Cartesian plans to attend

Conference date/time

May 19, 2026 at 3:00 p.m. ET

Scheduled fireside chat time at NASDAQ

Historical Context

5 past events · Latest: May 04

5 events

1. May 04

   Inducement option grants

   24h Move

   +11.4%

   New employees received 317,200 options at a $6.22 exercise price.

2. Apr 30

   Q1 2026 earnings

   24h Move

   -3.9%

   Reported $120.4M cash, ATM proceeds, and multiple advancing clinical trials.

3. Apr 02

   Inducement option grants

   24h Move

   -2.0%

   Granted 52,450 options at $6.39 to two new employees.

4. Mar 09

   FY 2025 results

   24h Move

   +31.7%

   Announced $126.9M cash, runway into mid-2027, and trial progress.

5. Feb 23

   Conference participation

   24h Move

   +0.7%

   Planned presentations at TD Cowen, Leerink, and Needham investor events.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FREDERICK, Md., May 12, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in a fireside chat at the H.C. Wainwright 4^th Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19, 2026, at 3:00 p.m. ET.

A live webcast of the presentation and fireside chat is expected to be accessible in the Events section of the Company’s website at www.cartesiantherapeutics.com, where an archived replay of the events will also be available for a limited time.

About Cartesian Therapeutics

Cartesian Therapeutics is a late clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis, Phase 2 clinical development in myositis, specifically dermatomyositis and antisynthetase syndrome, and in Phase 1/2 clinical development for pediatric autoimmune diseases, including juvenile dermatomyositis. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X.

Investor Contact

Megan LeDuc
Associate Director, Investor Relations
megan.leduc@cartesiantx.com

Media Contact

David Rosen
Argot Partners
david.rosen@argotpartners.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Cartesian Therapeutics (RNAC) present at the H.C. Wainwright 4th Annual BioConnect Investor Conference?

Cartesian Therapeutics will participate in a fireside chat on May 19, 2026, at 3:00 p.m. ET. According to the company, the session is part of the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ.

How can investors watch Cartesian Therapeutics' RNAC fireside chat at the 2026 BioConnect Investor Conference?

Investors can watch a live webcast of Cartesian Therapeutics’ fireside chat via the Events section of the company’s website. According to the company, an archived replay of the events will also be available online for a limited time after the conference.

What type of company is Cartesian Therapeutics (NASDAQ: RNAC)?

Cartesian Therapeutics is described as a late clinical-stage biotechnology company focused on pioneering cell therapy for autoimmune diseases. According to the company, this positioning underpins its participation in investor conferences like the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ.

Where will the Cartesian Therapeutics (RNAC) 2026 BioConnect conference replay be available?

The replay of Cartesian Therapeutics’ fireside chat is expected to be available in the Events section of the company’s website. According to the company, this archived replay will remain accessible for a limited time following the May 19, 2026 presentation.